Certification

Vimta provides end-to-end contract testing and research across five sectors: pharma & biopharma (bioanalytical, clinical, CMC, stability, drug discovery support), food & personal care, electricals & electronics (EMI/EMC, safety, performance), environment health & safety, and crop care & specialty chemicals. Services span method development, regulatory testing, GLP/GMP studies, and product certification — all delivered from our NABL- and GLP-accredited facilities in Hyderabad.

Our labs operate under NABL (ISO/IEC 17025), GLP (OECD principles), USFDA inspections, WHO-GMP, CDSCO, FSSAI, BIS, and DSIR, among 30+ international accreditations. Reports issued by Vimta are accepted by regulators in the US, EU, Japan, and across Asia-Pacific, so sponsors can file submissions globally without redundant re-testing.

Share your study outline or sample details through our Contact form, email enquiry@vimta.com, or call the Hyderabad facility directly. Our project management team typically reaches out within one business day with a scoped quote, turnaround estimate, and shipping instructions. For regulated-study sponsors we also sign CDAs upfront.

Turnaround depends on matrix, method status, and regulatory scope. Routine analytical testing is usually 5–10 business days; validated bioanalytical sample analysis runs on scheduled batches with study-specific timelines; GLP toxicology and stability studies follow protocol-defined durations. Every quote includes a concrete timeline and milestone plan so you can align internal submissions.

Yes. Every engagement starts with a mutual CDA, followed by a study-specific contract covering data ownership, retention, and audit rights. Study data is held in 21 CFR Part 11–compliant systems with role-based access, and our QA unit archives raw data under GLP/GCP record-keeping rules. Sponsor representatives can audit studies on-site or remotely by prior arrangement.